{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:32:49Z","timestamp":1787761969474,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      A 76-year-old female received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac, Sinovac\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , Beijing, China) and subsequently experienced chest discomfort. A computed tomography performed 1 day after vaccination showed multiple infiltrations in both lungs and ground-glass shadows in both lung fields. Her fingertip oxygen saturation was 81% and there was widespread wheezing on physical examination. Based on these findings, the patient was hospitalized with a preliminary diagnosis of drug-induced pneumonitis and acute asthma exacerbation due to a SARS-CoV-2 vaccine. During her hospitalization, 40 mg\/d systemic steroid, 4 times a day salbutamol nebulized, 2 L\/min inhaled oxygen therapy and 400 mg\/d moxifloxacin intravenous were administered for 5 days. One month later, the thorax computed tomography scan revealed that the previous findings were almost completely regressed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2045-9912.326003","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T05:26:52Z","timestamp":1686547612000},"page":"67-68","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac\u00ae)"],"prefix":"10.4103","volume":"12","author":[{"given":"Fatih","family":"Uzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"Cilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20240907","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/s13063-020-04775-4","article-title":"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Palacios","year":"2020","journal-title":"Trials"},{"key":"R3-7-20240907","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"R4-7-20240907","doi-asserted-by":"crossref","first-page":"n912","DOI":"10.1136\/bmj.n912","article-title":"What do we know about China\u2019s covid-19 vaccines","volume":"373","author":"Baraniuk","year":"2021","journal-title":"BMJ"},{"key":"R5-7-20240907","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R6-7-20240907","doi-asserted-by":"crossref","first-page":"585354","DOI":"10.3389\/fimmu.2020.585354","article-title":"A review of the progress and challenges of developing a vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front Immunol"},{"key":"R9-7-20240907","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/S0140-6736(21)00464-5","article-title":"(18)F-fluorodeoxyglucose PET\/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine","volume":"397","author":"Steinberg","year":"2021","journal-title":"Lancet"},{"key":"R10-7-20240907","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2169\/internalmedicine.9399-17","article-title":"Seasonal influenza vaccine-induced pneumonitis presenting with multiple pulmonary nodules","volume":"57","author":"Numata","year":"2018","journal-title":"Intern Med"}],"container-title":["Medical Gas Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.326003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:12:44Z","timestamp":1787760764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2045-9912.326003"}},"subtitle":["a case report"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/2045-9912.326003","relation":{},"ISSN":["2045-9912"],"issn-type":[{"value":"2045-9912","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}